eMedicine Specialties > Cardiology > Myocardial Disease and Cardiomyopathies

Cardiomyopathy, Hypertrophic

Author: Michael E Zevitz, MD, Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice
Contributor Information and Disclosures

Updated: Aug 27, 2009

Introduction

Background

Hypertrophic cardiomyopathy (HCM) is a genetic disorder that is typically inherited in an autosomal dominant fashion with variable penetrance and variable expressivity. The disease has complex symptomatology and potentially devastating consequences for patients and their families.1 The disorder has a variable presentation and carries a high incidence of sudden death. In fact, HCM is the leading cause of sudden cardiac death in both preadolescent and adolescent children. The hallmark of the disorder is myocardial hypertrophy that is inappropriate, often asymmetric, and occurs in the absence of an obvious inciting hypertrophy stimulus. This hypertrophy can occur in any region of the left ventricle but frequently involves the interventricular septum, which results in an obstruction of flow through the left ventricular (LV) outflow tract.

Decades ago, HCM was written about and known as idiopathic hypertrophic subaortic stenosis (IHSS) or asymmetric septal hypertrophy (ASH). These terms were replaced by hypertrophic cardiomyopathy because the segmental hypertrophy can occur in any segment of the ventricle, not just the septum. Furthermore, this entity can present without subaortic obstruction to flow, yet still carry the same ominous risk of arrhythmogenic sudden death and many of its clinical symptoms.

HCM can be separated into obstructive and nonobstructive types. Obstructive HCM is due to midsystolic obstruction of flow through the LV outflow tract as a result of a Bernoulli effect–induced systolic anterior mitral valve movement toward the septum. The significance of this obstruction, however, is highly controversial. Some investigators and experts believe the obstruction has less to do with the overall hemodynamic and pathophysiologic manifestations of this entity than the inappropriate segmental hypertrophy, which, with its increased myocardial oxygen consumption and substrate for fatal ventricular arrhythmias, has much more significance in the overall clinical picture of this entity and the treatment and prognosis of HCM.

Pathophysiology

Since the initial descriptions of hypertrophic cardiomyopathy, the feature that has attracted the greatest attention is the dynamic pressure gradient across the LV outflow tract. The pressure gradient appears to be related to further narrowing of an already small outflow tract (by the marked asymmetric septal hypertrophy and possibly an abnormal location of the mitral valve) by the systolic anterior motion of the mitral valve against the hypertrophied septum. The likely cause of this is a Venturi effect resulting from increased ejection velocity produced by the abnormal LV outflow tract orientation and geometry.

In addition, most patients have abnormal diastolic function, whether or not a pressure gradient is present, which impairs ventricular filling and increases filling pressure, despite a normal or small ventricular cavity. These patients have abnormal calcium kinetics and subendocardial ischemia, which are related to the profound hypertrophy and myopathic process.

Hypertrophic cardiomyopathy is a familial disease with an autosomal dominant pattern of inheritance.2 There are defects in several of the genes encoding for the sarcomeric proteins, such as myosin heavy chain, actin, tropomyosin, and titin.3,4 Multiple mutations have been identified, with genotype-specific risks of mortality and degree of hypertrophy. Interestingly, the genetic basis of ventricular hypertrophy does not directly correlate with prognostic risk stratification. Patients with some mutations, such as specific tropomyosin substitutions, have only a mild degree of ventricular hypertrophy, with little or no LV outflow tract obstruction, but they still carry a disproportionately high risk of sudden death.5

Frequency

United States

HCM is reported in 0.5% of the outpatient population referred for echocardiography.6 The overall prevalence of HCM is low and has been estimated to occur in 0.05-0.2% of the population.7 Morphologic evidence of disease is found by echocardiography in approximately 25% of first-degree relatives of patients with HCM. Genetic testing still is in the early stages of research development but can be used to identify asymptomatic family members with the same mutation as the proband (index case).

Mortality/Morbidity

HCM survival rates have improved over the past decades, with a 2006 study reporting that published sudden death rates over the past 10 years being lower than previously published figures (median 1.0% (range 0.1–1.7) v 2.0% (0–3.5)). Nevertheless, HCM still carries a high risk for mortality and morbidity.8

  • Sudden death: Most patients are asymptomatic. Unfortunately, the first clinical manifestation of the disease in such individuals may be sudden death, likely from ventricular tachycardia or fibrillation. Younger patients, particularly children, have a much higher mortality rate. Children have a much greater degree of ventricular hypertrophy and are much more symptomatic early on in the disease course, most likely because more malignant genotypes are present earlier in life. The more benign mutations do not elicit a clinical or echocardiographic phenotype or symptoms in the pediatric population. Death often is sudden, unexpected, and typically is associated with sports or vigorous exertion. Early diagnosis is of prime importance in order to prescribe an appropriate level of safe activity. Screening of first-degree relatives is useful to identify additional affected family members prior to the onset of significant symptoms or sudden death.9,10,11
  • Arrhythmia: Patients can have a myriad of arrhythmias, including atrial fibrillation, atrial flutter, ventricular ectopy, ventricular tachycardia, and ventricular fibrillation. These patients are among the highest-risk group for ventricular fibrillation and pose difficult therapeutic decisions for risk reduction.
  • Heart failure: Patients have a high likelihood of recurrent heart failure resulting from both mitral regurgitation and profound diastolic dysfunction. HCM is a progressive condition that worsens over time, as does the gradient across the LV outflow tract if left untreated. Systolic function usually is well preserved until the late stages of the disease. Angina is rare in children but common in adults. Syncope and presyncope are common and may identify individuals at high risk for sudden death.

Sex

  • HCM is slightly more common in males than in females. However, the genetic inheritance pattern is autosomal dominant, without sex predilection. Modifying genetic, hormonal, and environmental factors may lead to a higher likelihood of identification in males, increased symptomatology, or higher degrees of LV outflow obstruction, with more prominent findings upon physical examination.
  • HCM usually presents at a younger age in females. Females tend to be more symptomatic and are more likely to be disabled by their symptoms than males.

Age

  • In general, HCM has a bimodal peak of occurrence. The most common presentation is in the third decade of life, but it may present in persons of any age, from newborns to elderly individuals.
  • In children, inherited cases are found in an age range from newborn (ie, stillborn babies) to adult. The peak incidence is in these cases is in the second decade of life.
  • In adults, the peak distribution is in the fourth through the sixth decades of life.

Clinical

History

Symptoms can include sudden cardiac death, dyspnea, syncope and presyncope, angina, palpitations, orthopnea, paroxysmal nocturnal dyspnea, congestive heart failure, and dizziness.

  • Sudden cardiac death
    • This is the most devastating presenting manifestation of HCM. It has the highest incidence in preadolescent and adolescent children and is particularly related to extreme exertion. The risk of sudden death in children is as high as 6% per year.
    • In more than 80% of cases, the arrhythmia that causes sudden death is ventricular fibrillation. Many of these cases degenerate into ventricular fibrillation from rapid atrial arrhythmias, such as fibrillation, supraventricular tachycardia, or Wolff-Parkinson-White syndrome, while others result from ventricular tachycardia and low cardiac output hemodynamic collapse.
  • Dyspnea
    • This is the most common presenting symptom, occurring in as many as 90% of symptomatic patients.
    • Dyspnea largely is a consequence of elevated LV diastolic filling pressures (and transmission of those elevated pressures back into the pulmonary circulation). The elevated LV filling pressures principally are caused by impaired diastolic compliance as a result of marked hypertrophy of the ventricle.
  • Syncope
    • Syncope is a very common symptom, resulting from inadequate cardiac output upon exertion or from cardiac arrhythmia. It occurs more commonly in children and young adults with small LV chamber size and evidence of ventricular tachycardia upon ambulatory monitoring.
    • Alternatively, syncope may be caused by arrhythmias, either tachycardias or bradycardias. Some patients with HCM have abnormalities in sinus node function, leading to sick sinus syndrome with alternating tachyarrhythmias and bradyarrhythmias or severe bradyarrhythmias.
    • Syncope and presyncope identify patients at high risk of sudden death and warrant an urgent workup and aggressive treatment.
  • Presyncope
    • Presyncope includes "graying-out" spells that occur in the erect posture and can be relieved by immediately lying down.
    • They occur quite commonly and identify patients at high risk for sudden death.
    • These symptoms are exacerbated by vagal stimulation. Presyncope also may occur with nonsustained atrial or ventricular tachyarrhythmias.
  • Angina
    • Typical symptoms of angina are quite common in patients with HCM and may occur in the absence of detectable coronary atherosclerosis.
    • Impaired diastolic relaxation and markedly increased myocardial oxygen consumption are caused by ventricular hypertrophy that results in subendocardial ischemia, particularly during exertion.
  • Palpitations
    • Palpitations are common.
    • These result from arrhythmias, such as premature atrial and ventricular beats, sinus pauses, atrial fibrillation, atrial flutter, supraventricular tachycardia, and ventricular tachycardia.
  • Orthopnea and paroxysmal nocturnal dyspnea
    • These are early signs of congestive heart failure and, while relatively uncommon, are observed in patients with severe HCM and result from impaired diastolic function and elevated LV filling pressure.
    • Orthopnea and paroxysmal nocturnal dyspnea result from pulmonary venous congestion.
  • Congestive heart failure
    • This is relatively uncommon but is observed in patients with severe HCM.
    • It may occur as a result of a combination of impaired diastolic function and subendocardial ischemia.
    • Systolic function in these patients almost always is well preserved.
  • Dizziness
    • Dizziness is common in patients with HCM with elevated pressure gradients across the LV outflow tract. It is worsened by exertion and may be exacerbated by hypovolemia following high levels of exertion or increased insensible fluid loss (eg, during extreme heat).
    • Dizziness also may occur as a result of maneuvers, such as rapid standing or Valsalva during defecation, or certain medications, such as diuretics, nitroglycerin, and vasodilating antihypertensive agents, that decrease preload and afterload and increase the pressure gradient across the LV outflow tract.
    • Dizziness also may be secondary to arrhythmia-related hypotension and decreased cerebral perfusion. Nonsustained arrhythmias often cause symptoms of dizziness, lightheadedness, and presyncope, whereas sustained arrhythmias are more likely to lead to syncope, collapse, and/or sudden cardiac death.

Physical

  • Double apical impulse results from a forceful left atrial contraction against a highly noncompliant left ventricle. This occurs quite commonly in adults.
  • Triple apical impulse results from a late systolic bulge that occurs when the heart is almost empty and is performing near-isometric contraction. This is a highly characteristic finding of HCM; however, it occurs less frequently than the double apical impulse.
  • First heart sound is normal.
  • Second heart sound usually is normally split, but in some patients with severe outflow gradients, it is paradoxically split.
  • An S3 gallop is common in children, but it does not have the same ominous significance as in patients with valvular aortic stenosis. When it occurs in adults, it signifies decompensated congestive heart failure.
  • A fourth heart sound, an S4, frequently is heard and results from atrial systole against a highly noncompliant left ventricle.
  • Jugular venous pulse reveals a prominent a wave caused by diminished right ventricular compliance secondary to massive hypertrophy of the ventricular septum.
  • Double carotid arterial pulse is common. The carotid pulse rises quickly because of the increased velocity of blood through the LV outflow tract and into the aorta. The carotid pulse then declines in mid systole as the gradient develops. This is followed by a secondary rise in carotid pulsation during late systole.
  • Apical precordial impulse frequently is displaced laterally and usually is abnormally forceful and enlarged.
  • Systolic ejection murmur typically is a systolic ejection crescendo-decrescendo murmur, which is best heard between the apex and left sternal border and radiates to the suprasternal notch but not to the carotid arteries or neck. The murmur and the gradient across the LV outflow tract diminish with any increase in preload (eg, Mueller maneuver, squatting) or increase in afterload (eg, handgrip). The murmur and the gradient increase with any decrease in preload (eg, Valsalva maneuver, nitrate administration, diuretic administration, standing) or with any decrease in afterload (eg, vasodilator administration).
  • Holosystolic murmur at the apex and axilla of mitral regurgitation is heard in patients with systolic anterior motion of the mitral valve and significant LV outflow gradients.
  • Diastolic decrescendo murmur of aortic regurgitation is heard in 10% of patients, although mild aortic regurgitation can be detected by Doppler echocardiography in 33% of patients.

Causes

  • Abnormal calcium kinetics
    • The actual causes of HCM include defects in the genes encoding for several of the sarcomeric proteins. Additional data link abnormal myocardial calcium kinetics as the cause of the inappropriate myocardial hypertrophy and specific features of HCM, particularly in patients with diastolic functional abnormalities.
    • Abnormal myocardial calcium kinetics and abnormal calcium fluxes from an increase in the number of calcium channels result in an increase in intracellular calcium concentration, which, in turn, may produce hypertrophy and cellular disarray.
  • Genetic causes 
    • Familial HCM occurs as an autosomal dominant Mendelian-inherited disease in approximately 50% of cases. Some, if not all, of the sporadic forms of the disease may be caused by spontaneous mutations.
    • At least 6 different genes on at least 4 chromosomes are associated
    • Familial HCM occurs as an autosomal dominant Mendelian-inherited disease in approximately 50% of cases. Some, if not all, of the sporadic forms of the disease may be caused by spontaneous mutations.
    • At least 6 different genes on at least 4 chromosomes are associated with HCM, with more than 50 different mutations discovered thus far. Familial HCM is a genetically heterogenous disease in that it can be caused by genetic defects at more than one locus.
    • In 1989, Seidman and collaborators first reported the genetic basis for HCM. They reported the existence of a disease gene located on the long arm of chromosome 14. Subsequently, they found this to be the gene encoding for beta cardiac myosin heavy chain.
    • Wide variation exists in the phenotypic expression of a given mutation of a given gene, with variability in clinical symptoms and the degree of hypertrophy expressed. Phenotypic variability is related to the differences in genotype, with specific mutations associated with particular symptoms, the degree of hypertrophy, and the prognosis.9
  • Other suggested causes
    • Abnormal sympathetic stimulation: Heightened responsiveness of the heart to the excessive production of catecholamines or the reduced neuronal uptake of norepinephrine might cause HCM.
    • Abnormally thickened intramural coronary arteries: These do not dilate normally, which leads to myocardial ischemia. This progresses to myocardial fibrosis and abnormal compensatory hypertrophy.
    • Subendocardial ischemia: This is related to abnormalities of the cardiac microcirculation that deplete the energy stores essential for the sequestration of calcium during diastole. Subendocardial ischemia results in persistent interaction of the contractile elements during diastole and increased diastolic stiffness.
    • Cardiac structural abnormalities: These include a catenoid configuration of the septum, which results in myocardial cell hypertrophy and disarray.

More on Cardiomyopathy, Hypertrophic

Overview: Cardiomyopathy, Hypertrophic
Differential Diagnoses & Workup: Cardiomyopathy, Hypertrophic
Treatment & Medication: Cardiomyopathy, Hypertrophic
Follow-up: Cardiomyopathy, Hypertrophic
Multimedia: Cardiomyopathy, Hypertrophic
References
[ CLOSE WINDOW ]

References

  1. Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D, Clinical Electrophysiology Service, Department of Medicine, Montreal Heart Institute, University of Montreal, Montreal, et al. Sudden death and hypertrophic cardiomyopathy: a review. Can J Cardiol. 2005; 21(5):441-8 (ISSN: 0828-282X).

  2. Colombo MG, Botto N, Vittorini S, Paradossi U, Andreassi MG. Clinical utility of genetic tests for inherited hypertrophic and dilated cardiomyopathies. Cardiovasc Ultrasound. Dec 19 2008;6:62. [Medline].

  3. Morimoto S. Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc Res. Mar 1 2008;77(4):659-66. [Medline].

  4. Soor GS, Luk A, Ahn E, Abraham JR, Woo A, Ralph-Edwards A, et al. Hypertrophic cardiomyopathy: current understanding and treatment objectives. J Clin Pathol. Mar 2009;62(3):226-35. [Medline].

  5. Van Driest SL, Ackerman MJ, Ommen SR, Shakur R, Will ML, Nishimura RA, et al. Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation. Dec 10 2002;106(24):3085-90. [Medline].

  6. Maron BJ, Peterson EE, Maron MS, Peterson JE. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol. Mar 15 1994;73(8):577-80. [Medline].

  7. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. Aug 15 1995;92(4):785-9. [Medline].

  8. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. Jun 2006;92(6):785-91. [Medline].

  9. [Guideline] Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. Nov 5 2003;42(9):1687-713. [Medline].

  10. DeRose JJ Jr, Banas JS Jr, Winters SL. Current perspectives on sudden cardiac death in hypertrophic cardiomyopathy. Prog Cardiovasc Dis. May-Jun 1994;36(6):475-84. [Medline].

  11. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation. Jun 1982;65(7):1388-94. [Medline].

  12. Musat D, Sherrid MV. Echocardiography in the treatment of hypertrophic cardiomyopathy. Anadolu Kardiyol Derg. Dec 2006;6 Suppl 2:18-26. [Medline].

  13. Soor GS, Luk A, Ahn E, Abraham JR, Woo A, Ralph-Edwards A, et al. Hypertrophic cardiomyopathy: current understanding and treatment objectives. J Clin Pathol. Mar 2009;62(3):226-35. [Medline].

  14. [Guideline] Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm. Jun 2008;5(6):934-55. [Medline].

  15. Topilski I; Sherez J; Keren G; Copperman I, Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel. talitop@biu.013.net.il. Long-term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy >50 years of age. Am J Cardiol. 2006;97(12):1769-1775.

  16. Galve E, Sambola A, Saldaña G, Quispe I, Nieto E, Diaz A, et al. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy. A 10-year follow-up study. Heart. May 28 2009;[Medline].

  17. Silva LA, Fernández EA, Martinelli Filho M, Costa R, Siqueira S, Ianni BM, et al. Cardiac pacing in hypertrophic cardiomyopathy: a cohort with 24 years of follow-up. Arq Bras Cardiol. Oct 2008;91(4):250-6, 274-80. [Medline].

  18. Hagège AA, Desnos M. New trends in treatment of hypertrophic cardiomyopathy. Arch Cardiovasc Dis. May 2009;102(5):441-7. [Medline].

  19. Jassal DS; Neilan TG; Fifer MA; Palacios IF; Lowry PA; Vlahakes GJ; Picard MH; Yoerger DM, Cardiac Ultrasound Laboratory, Cardiology Division, Massachusetts General Hospital, Boston, MA 02114, et al. Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J. 2006; 27(15):1805-10 (ISSN: 0195-668X).

  20. Streit S, Walpoth N, Windecker S, Meier B, Hess O. Is alcohol ablation of the septum associated with recurrent tachyarrhythmias?. Swiss Med Wkly. Dec 1 2007;137(47-48):660-8. [Medline].

  21. You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Am Heart J. Nov 2007;154(5):899-907. [Medline].

  22. Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol. Oct 1994;24(4):880-5. [Medline].

  23. Thompson PD, Franklin BA, Balady GJ, Blair SN, Corrado D, Estes NA 3rd, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation. May 1 2007;115(17):2358-68. [Medline].

  24. Counihan PJ, McKenna WJ. Low-dose amiodarone for the treatment of arrhythmias in hypertrophic cardiomyopathy. J Clin Pharmacol. May 1989;29(5):436-8. [Medline].

  25. Fananapazir L, Leon MB, Bonow RO, et al. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol. Jan 15 1991;67(2):169-74. [Medline].

  26. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. Mar 13 2002;287(10):1308-20. [Medline].

  27. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. Jun 2006;92(6):785-91. [Medline].

  28. Armstrong AT, Binkley PF, Baker PB, et al. Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol. Sep 1998;32(3):704-10. [Medline].

  29. Biagini E; Spirito P; Leone O; Picchio FM; Coccolo F; Ragni L; Lofiego C; Grigioni F; Potena L; Rocchi G; Bacchi-Reggiani L; Boriani G; Prandstraller D; Arbustini E; Branzi A; Rapezzi C, Institute of Cardiology, University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy. Heart transplantation in hypertrophic cardiomyopathy. Am J Cardiol. (ISSN: 0002-9149). 2008;101(3):387-92.

  30. Bonne G, Carrier L, Richard P, et al. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res. Sep 21 1998;83(6):580-93. [Medline].

  31. Bonow RO. Left ventricular diastolic function in hypertrophic cardiomyopathy. Herz. Feb 1991;16(1):13-21. [Medline].

  32. Brandenburg RO. Syncope and sudden death in hypertrophic cardiomyopathy. J Am Coll Cardiol. Apr 1990;15(5):962-4. [Medline].

  33. Braunwald E. Hypertrophic cardiomyopathy--continued progress. N Engl J Med. Mar 23 1989;320(12):800-2. [Medline].

  34. Braunwald E, Wynne J. The Cardiomyopathies and Myocarditides. In: Heart disease: A textbook of cardiovascular medicine. 7th ed. Philadelphia, Pa: Elsevier Saunders; 2005. 2005;1667-1682.

  35. Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: an introduction to pathology and pathogenesis. Br Heart J. Dec 1994;72(6 Suppl):S2-3. [Medline].

  36. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. Sep 1993;22(3):796-804. [Medline].

  37. Elliott PM, Brecker SJ, McKenna WJ. Diastolic dysfunction in hypertrophic cardiomyopathy. Eur Heart J. Aug 1998;19(8):1125-7. [Medline].

  38. Fananapazir L, Cannon RO 3rd, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation. Jun 1992;85(6):2149-61. [Medline].

  39. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation. Sep 1992;86(3):730-40. [Medline].

  40. Fananapazir L, Epstein SE. Hemodynamic and electrophysiologic evaluation of patients with hypertrophic cardiomyopathy surviving cardiac arrest. Am J Cardiol. Feb 1 1991;67(4):280-7. [Medline].

  41. Hayashida W, Kumada T, Kohno F, et al. Left ventricular regional relaxation and its nonuniformity in hypertrophic nonobstructive cardiomyopathy. Circulation. Oct 1991;84(4):1496-504. [Medline].

  42. Hintringer F, Nesser HJ, Niel J, et al. Pacing in distal left ventricular hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. Sep 1998;21(9):1828-30. [Medline].

  43. Kubo T; Gimeno JR; Bahl A; Steffensen U; Steffensen M; Osman E; Thaman R; Mogensen J; Elliott PM; Doi Y; McKenna WJ, Department of Medicine, University College London, London, United Kingdom. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol. 2007; (ISSN: 1558-3597). 2007;49(25):2419-26.

  44. Losi MA, Betocchi S, Manganelli F, et al. Pattern of left ventricular filling in hypertrophic cardiomyopathy. Assessment by Doppler echocardiography and radionuclide angiography. Eur Heart J. Aug 1998;19(8):1261-7. [Medline].

  45. Louie EK, Edwards LC 3rd. Hypertrophic cardiomyopathy. Prog Cardiovasc Dis. Jan-Feb 1994;36(4):275-308. [Medline].

  46. Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol. Sep 15 1998;82(6):774-8. [Medline].

  47. Maron BJ. Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: too soon for a rush to judgment?. J Am Coll Cardiol. Feb 1996;27(2):431-2. [Medline].

  48. Maron BJ. Q waves in hypertrophic cardiomyopathy: a reassessment. J Am Coll Cardiol. Aug 1990;16(2):375-6. [Medline].

  49. Maron BJ, Cecchi F, McKenna WJ. Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. Br Heart J. Dec 1994;72(6 Suppl):S13-8. [Medline].

  50. Maron BJ, Klues HG. Surviving competitive athletics with hypertrophic cardiomyopathy. Am J Cardiol. Jun 1 1994;73(15):1098-104. [Medline].

  51. McDonald KM, Maurer B. Permanent pacing as treatment for hypertrophic cardiomyopathy. Am J Cardiol. Jul 1 1991;68(1):108-10. [Medline].

  52. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation. Nov 1989;80(5):1489-92. [Medline].

  53. Piacenza JM, Kirkorian G, Audra PH, Mellier G. Hypertrophic cardiomyopathy and pregnancy. Eur J Obstet Gynecol Reprod Biol. Sep 1998;80(1):17-23. [Medline].

  54. Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol. May 1990;15(6):1279-85. [Medline].

  55. Sanghvi NK; Tracy CM, Department of Medicine, George Washington University Hospital, Washington, DC. nsanghvi@gwu.edu. Sustained ventricular tachycardia in apical hypertrophic cardiomyopathy, midcavitary obstruction, and apical aneurysm. Pacing Clin Electrophysiol. 2007; 30(6):799-803 (ISSN: 0147-8389).

  56. Seiler C, Hess OM, Schoenbeck M, et al. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. J Am Coll Cardiol. Mar 1 1991;17(3):634-42. [Medline].

  57. Shapiro LM. Hypertrophic cardiomyopathy in the elderly. Br Heart J. May 1990;63(5):265-6. [Medline].

  58. Shirani J, Maron BJ, Cannon RO 3rd, et al. Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. Am J Cardiol. Aug 15 1993;72(5):434-40. [Medline].

  59. Spirito P, Bellone P. Natural history of hypertrophic cardiomyopathy. Br Heart J. Dec 1994;72(6 Suppl):S10-2. [Medline].

  60. Spirito P, Lakatos E, Maron BJ. Degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation. Am J Cardiol. May 1 1992;69(14):1217-22. [Medline].

  61. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol. Mar 15 1990;15(4):808-13. [Medline].

  62. ten Berg JM, Suttorp MJ, Knaepen PJ, et al. Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow-up after Morrow septal myectomy. Circulation. Oct 1994;90(4):1781-5. [Medline].

  63. Watkins H. Multiple disease genes cause hypertrophic cardiomyopathy. Br Heart J. Dec 1994;72(6 Suppl):S4-9. [Medline].

  64. Webb JG, Sasson Z, Rakowski H, et al. Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates. J Am Coll Cardiol. Jan 1990;15(1):83-90. [Medline].

  65. Wigle ED. Impaired left ventricular relaxation in hypertrophic cardiomyopathy: relation to extent of hypertrophy. J Am Coll Cardiol. Mar 15 1990;15(4):814-5. [Medline].

  66. Williams L; Frenneaux M, Department of Cardiovascular Medicine, University of Birmingham, Edgbaston, Birmingham, West Midlands, et al. Syncope in hypertrophic cardiomyopathy: mechanisms and consequences for treatment. Europace. 2007; 9(9):817-22 (ISSN: 1099-5129).

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

hypertrophic cardiomyopathy, HCM, hypertrophic obstructive cardiomyopathy, idiopathic hypertrophic subaortic stenosis, IHSS, muscular subaortic stenosis, asymmetric septal hypertrophy, ASH, sudden death, sudden cardiac death, SCD, arrhythmogenic sudden death, myocardial hypertrophy, cardiomyopathy

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Michael E Zevitz, MD, Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice
Michael E Zevitz, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Medical Association, and Michigan State Medical Society
Disclosure: Nothing to disclose.

Medical Editor

Gary E Sander, MD, PhD, Professor, Department of Internal Medicine, Division of Cardiology, Tulane University Health Sciences Center
Gary E Sander, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Heart Association, American Society of Hypertension, Heart Failure Society of America, Louisiana State Medical Society, and Southern Society for Clinical Investigation
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Frank M Sheridan, MD, Cardiology, Providence Everett Medical Center
Frank M Sheridan, MD is a member of the following medical societies: American College of Cardiology, American Heart Association, and Society for Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

CME Editor

Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital
Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.